Data provided by Lucintel projects that the future of the global medical device industry will provide opportunities in public and private hospitals.
| NEW YORK, /PRNewswire/ -- Data provided by Lucintel projects that the future of the global medical device industry will provide opportunities in public and private hospitals. The sector is expected to reach an estimated USD 409.5 Billion by 2023, while growing at a CAGR of 4.5% from 2018 to 2023. The major drivers for the growth of this industry are health care expenditures, technological developments, the aging population, and chronic diseases. By application, the medical device industry can be segmented into surgical and infection control devices, general medical devices, cardiovascular devices, orthopedic devices, home healthcare devices, and others. PCT Ltd. (OTC: PCTL), MEDNAX, Inc. (NYSE: MD), Owens & Minor, Inc. (NYSE: OMI), Smith & Nephew plc (NYSE: SNN), SCYNEXIS, Inc. (NASDAQ: SCYX) The infection control segment is expected to grow at a fast rate. According to MarketsandMarkets, the global infection control market is expected to reach USD 21.06 Billion by 2022 from USD 15.35 Billion in 2017 and at a CAGR of 6.5%. The research indicates that the increasing use of e-beam sterilization, rising importance of single-use medical nonwovens and medical devices are further increasing the demand for disinfection and sterilization products and services. Based on end user, the global infection control market is segmented into hospitals & clinics, medical devices companies, food industry, life sciences industry, pharmaceutical companies, and other end users. Hospitals & clinics are projected to register the highest CAGR during the forecast period. The growth is attributed to the rising incidence of HAIs (Hospital Acquired Infection), growing volume of surgical procedures, increasing cost burden due to the rising geriatric population & incidence of chronic diseases and increasing number of hospitals across the globe. PCT Ltd. (OTC: PCTL) just early today announced breaking news that, it has entered into a Master Services Agreement with a New York-based hospital supply and services company for the installation of two Annihilyzer® Infection Control Systems to prevent hospital-acquired infections (HAI’s) in hospitals in its market area. According to the Center for Disease Control & Prevention (CDC), “On any given day, about one in 25 hospital patients has at least one healthcare-associated infection.” Quoted in Clinical Leadership & Infection Control, Lynn White, MD, president of Patient Shield Concepts, said, "…the estimated direct medical cost of HAIs is around $10 billion annually, not including cost-shifting to private payers. Including cost-shifting, HAIs may cost closer to between $35 billion and $45 billion for acute-care hospitals annually. The total direct, indirect and nonmedical social costs of HAIs are estimated at around $96 billion to $147 billion annually, including loss of work, legal costs and other patient factors.” The Annihilyzer® Infection Control System produces on-site generated Electrochemically Activated cleaner and disinfectant fluid solutions that allow hospitals to move away from traditional disinfectants that are toxic and can cause harm to the housekeeping staff and patients to a cleaner and a disinfectant that are safe, environmentally sound and greatly reduce the damage to furnishings and equipment caused by toxic chemicals, yet is effective against HAI’s like MRSA, VRE and C-diff. PCT Health’s system tracks the life cycle of the cleaner and disinfectant and alerts the user before the product is no longer at its optimum effectiveness. The tracking system can be customized to track employees to ensure that all proper cleaning and disinfecting protocols are being performed during the cleaning process. This assists the hospital administration by supplying valuable data regarding the who, what, when and how all areas of the hospital are cleaned and disinfected. This system also incorporates the use of Electrostatic Smart Applicators that apply disinfectant to all surfaces. Human error associated with improper application and coverage of disinfectant is no longer an issue as the electrostatic applicators ensure that all surfaces are covered and wrapped with disinfectant. Fogging or misting systems are not time or cost effective whereas the electrostatic application process is more thorough and takes less time, so room turnover is much faster. The Annihilyzer® Infection Control System is very cost effective and performs well where other cleaning and disinfecting systems sometimes fail. For additional information about the Annihilyzer® Infection Control System, visit www.pcthealth.com . About PCT: PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, “PCTL” aspires to and is actively engaged in preparations for up-listing to a national securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to gain market share. PCT Corp’s business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment, disinfecting fluid solutions and PCT Corp’s patented tracking system to hospitals and other facilities for the documentable remediation of Hospital Acquired Infections (HAI’s) from organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas, as well as to sell ECA fluid solutions to agricultural markets for the remediation, control and suppression of microbial contamination and disease of certain commercial crops. The Company’s primary fluid solution, branded Hydrolyte®, is an EPA registered “hospital-level” disinfectant effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella. PCT Corp.'s proprietary equipment product line includes: 1) PCT Hydrolyte® Generators, 2) PCT Annihilyzer® Infection Control Systems, and 3) SurvivaLyte® equipment. The Hydrolyte® Generators produce large volumes of electrolyzed water for the agriculture, oil and gas, and fluid distribution markets. The Annihilyzer® Infection Control Systems, which boast patented RFID material tracking technology, Electrostatic Smart Applicators, on-site automated ECA generators, and Green Seal standards containing stringent performance, health, and sustainability criteria, are ideal for hospitals and healthcare facilities. The SurvivaLyte® unit is a portable, small volume generator with applications such as disaster recovery, emergency preparedness, remote on-site needs, farm and ranch, and personal use. PCT Corp’s unique patented systems and human-safe products provide next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial infection and infestation.” MEDNAX, Inc. (NYSE: MD) is a national health solutions partner based in Sunrise, Fla. comprised of the nation’s leading providers of physician services. MEDNAX, Inc. recently announced that it has partnered with Pacira Pharmaceuticals, Inc. to address the ongoing use of opioids during and after cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim through the implementation of an Enhanced Recovery after Cesarean Surgery (ERACS™) program. The collaborative will be multi-disciplinary in nature, engaging the expertise of maternal-fetal medicine physicians, anesthesiologists, obstetricians and perioperative nurses to improve the patient experience as well as maternal and infant health, reduce the total cost of care and enhance provider satisfaction. The ERACS™ program will encompass comprehensive educational and clinical implementation pathways. The overarching goals will be to educate clinical teams, shorten the length of postoperative hospital stays, reduce the use of opioid analgesics and improve postoperative pain control. Additionally, MEDNAX and Pacira will monitor a series of clinical quality, safety and value-based performance indicators including: reduced serious maternal and infant morbidity, reduced postoperative nausea and vomiting, lower rate of surgical site infections, lower rate of return to the operating room, lower rate of readmission to the hospital and lower total cost of care. Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company with integrated technologies, products, and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum of care. Owens & Minor announced earlier this year that it had completed the acquisition of the surgical and infection prevention (“S&IP”) business of Halyard Health, Inc., on April 30th, 2018, for approximately USD 710 Million in cash, subject to certain adjustments as provided in the Amended and Restated Purchase Agreement. With the acquisition of the Halyard S&IP business, a recognized leader in its segment, Owens & Minor takes a significant step in transforming its business into a global healthcare solutions provider. This transaction expands Owens & Minor’s reach into new markets around the world, develops its presence in the medical products segment, and opens new channels for growth. The acquisition will also add greater scale to Owens & Minor’s existing own-brand product portfolio and help to expand the company’s addressable markets. Smith & Nephew plc (NYSE: SNN) is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. Smith & Nephew recently announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of PICO Single Use Negative Pressure Wound Therapy (sNPWT). The MIB reports the prophylactic use of PICO as a potentially more effective alternative to standard surgical dressings in the prevention of surgical site complications (SSCs). This is the first and only MIB published by NICE on an NPWT device for preventing SSCs. “NICE MIBs are a great resource for NHS organisations, and are often a reference used by healthcare systems beyond the UK. Today we are delighted to see the NICE MIB support for the prophylactic use of PICO as an effective alternative for clinicians who look to reduce their rates of surgical site complications. This will provide them with the confidence to use PICO for their at-risk patients and procedures, in support of their efforts to achieve better economic and clinical outcomes,” said Paolo Di Vincenzo, Smith & Nephew’s SVP of Advanced Wound Management. “With PICO, we are keeping Smith & Nephew at the forefront of delivering pioneering solutions that continue to improve current standards of care, by reducing the burden and delivering better clinical and economic outcomes. PICO has shown significant clinical results in reducing life-threatening infections on closed surgical incisions, which has contributed significantly to improved patient outcomes, in a cost-effective portable solution.” SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the oral formulation of SCY-078, SCYNEXIS’s novel oral and intravenous antifungal agent, for the treatment of vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC. Additionally, SCYNEXIS previously announced that it has completed enrollment in the Phase 2b, dose-finding study of oral SCY-078 for the treatment of VVC (the DOVE study). “These designations from the FDA for the treatment of VVC and prevention of recurrent VVC highlight the significant unmet needs faced by women suffering from these widespread infections,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “We believe SCY-078 will provide a beneficial treatment option for healthcare providers and women not satisfied with existing therapies. Moreover, we can now make use of the QIDP and Fast Track designations across all current SCY-078 development programs, including VVC, invasive candidiasis and invasive aspergillosis.” Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/ About FinancialBuzz.com Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pct ltd. financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by paradigm convergence. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com . For further information: SOURCE FinancialBuzz.com | ||
Company Codes: OTC-BB:PCTL, NYSE:MD, NYSE:OMI, NYSE:SNN, NASDAQ-NMS:SCYX |
